Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ritalin And Adderall To Get Toxicology Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Review of the ADHD products by National Toxicology Program’s Center for the Evaluation of Risks to Human Reproduction is expected to take three to six months.

You may also be interested in...



“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says

Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.

PBMs Object To Real-Time Prior Authorization As Part Of E-Prescribing

Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”

E-Prescriber Access To Non-Preferred Drug Listings Is Industry Concern

Physicians should not have to scroll or click through new windows to see non-preferred and off-formulary drugs, Pfizer, J&J tell the standards subcommittee of the National Committee on Vital & Health Statistics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel